AZNAstraZenecaSigning up patients
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 101 (planned)
- Started
- Jul 27, 2026
- Main results expected
- Mar 6, 2031
- Fully finished
- Mar 6, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Adverse events (AEs) and serious AEs (SAEs)
Measured over: Through study completion, an average of 2 years
Dose-limiting toxicities (DLT)
Measured over: 28 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07681596 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC